Abbvie Inc (ABBV) Financial Statements

Analyzing AbbVie through the GoodMoat quality lens reveals a complex picture. The company's 10.0% YoY revenue growth is positive, though not in the high-growth category. The 24.6% operating margin is a strong indicator of profitability and suggests good cost control. However, the 6.9% profit margin is notably low for a major pharmaceutical company, indicating significant non-operating expenses, likely including amortization from past acquisitions. This directly impacts the reported P/E of 86.6x, which appears extreme for this level of bottom-line growth. On the positive side, the 4.9% Free Cash Flow (FCF) Yield, while not exceeding the >10-15% FCF margin framework ideal, demonstrates the company's ability to convert earnings to cash, supporting its 3.18% dividend. A key data point missing for a full balance sheet assessment is the Debt/Equity ratio; without it, a definitive health check is incomplete, though the substantial market cap suggests significant leverage is likely manageable. Overall, the quality is adequate with strong cash generation but is overshadowed by valuation metrics that appear unfavourable without clear evidence of accelerating profit growth to justify them. Analysis based on data as of 2024-05-15.